Related references
Note: Only part of the references are listed.Simultaneous targeting of TGF-β/PD-L1 synergizes with radiotherapy by reprogramming the tumor microenvironment to overcome immune evasion
Yan Lan et al.
CANCER CELL (2021)
Phase 1 study of SHR-1701, a bifunctional fusion protein targeting PD-L1 and TGF-beta, in patients with advanced solid tumors.
Dan Liu et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
SHR-1701, a bifunctional fusion protein targeting PD-L1 and TGF-beta, for advanced NSCLC with EGFR mutations: Data from a multicenter phase 1 study.
Meiqi Shi et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Phase Ib study of the anti-TGF-beta monoclonal antibody (mAb) NIS793 combined with spartalizumab (PDR001), a PD-1 inhibitor, in patients (pts) with advanced solid tumors.
Todd Michael Bauer et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Targeting transforming growth factor-β signaling for enhanced cancer chemotherapy
Jitang Chen et al.
THERANOSTICS (2021)
AVID200, first-in-class TGF-beta 1 and 3 selective and potent inhibitor: Safety and biomarker results of a phase I monotherapy dose-escalation study in patients with advanced solid tumors.
Timothy A Yap et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Selective inhibition of TGFβ1 activation overcomes primary resistance to checkpoint blockade therapy by altering tumor immune landscape
Constance J. Martin et al.
SCIENCE TRANSLATIONAL MEDICINE (2020)
Immunotherapeutic Potential of TGF-β Inhibition and Oncolytic Viruses
Christianne Groeneveldt et al.
TRENDS IN IMMUNOLOGY (2020)
Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Second-Line Treatment of Patients With NSCLC: Results From an Expansion Cohort of a Phase 1 Trial
Luis Paz-Ares et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
The Use of a Humanized NSG-β2m-/- Model for Investigation of Immune and Anti-tumor Effects Mediated by the Bifunctional Immunotherapeutic Bintrafusp Alfa
Y. Maurice Morillon et al.
FRONTIERS IN ONCOLOGY (2020)
Clinical development of therapies targeting TGF beta: current knowledge and future perspectives
D. Ciardiello et al.
ANNALS OF ONCOLOGY (2020)
Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma
Thomas Powles et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
TGF-β Mediated Immune Evasion in Cancer-Spotlight on Cancer-Associated Fibroblasts
Parisa Ghahremanifard et al.
CANCERS (2020)
The tumor microenvironment and radiotherapy response; a central role for cancer-associated fibroblasts
Marleen Ansems et al.
CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY (2020)
Idiopathic Pulmonary Fibrosis and Lung Cancer: Mechanisms and Molecular Targets
Beatriz Ballester et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Transforming Growth Factor-β Signaling in Immunity and Cancer
Eduard Batlle et al.
IMMUNITY (2019)
The prognostic role of soluble transforming growth factor-β related with soluble programmed death-ligand 1 in biliary tract cancer
Jin Won Kim et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
A Phase 2 Study of Galunisertib (TGF-β1 Receptor Type I Inhibitor) and Sorafenib in Patients With Advanced Hepatocellular Carcinoma
R. K. Kelley et al.
CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY (2019)
Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy Three-Year Follow-up of a Randomized Phase 3 Trial
Paolo A. Ascierto et al.
JAMA ONCOLOGY (2019)
Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012
Ranee Mehra et al.
BRITISH JOURNAL OF CANCER (2018)
Rationale for combination of therapeutic antibodies targeting tumor cells and immune checkpoint receptors: Harnessing innate and adaptive immunity through IgG1 isotype immune effector stimulation
Robert L. Ferris et al.
CANCER TREATMENT REVIEWS (2018)
TGF beta pathway inhibition in the treatment of non-small cell lung cancer
Pinar O. Eser et al.
PHARMACOLOGY & THERAPEUTICS (2018)
Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-β
Yan Lan et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
Association of TGF-β responsive signature with anti-tumor effect of vactosertib, a potent, oral TGF-β receptor type I (TGFBRI) inhibitor in patients with advanced solid tumors.
Vicki Leigh Keedy et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
Sanjeev Mariathasan et al.
NATURE (2018)
Elements of cancer immunity and the cancer-immune set point
Daniel S. Chen et al.
NATURE (2017)
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
J. Bellmunt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
TGF-β Family Signaling in Tumor Suppression and Cancer Progression
Joan Seoane et al.
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2017)
A novel bifunctional anti-PD-L1/TGF-β Trap fusion protein (M7824) efficiently reverts mesenchymalization of human lung cancer cells
Justin M. David et al.
ONCOIMMUNOLOGY (2017)
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Padmanee Sharma et al.
CELL (2017)
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
Willy Hugo et al.
CELL (2016)
Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma
Adil I. Daud et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort
Laura Q. M. Chow et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Three-year Follow up of GMCSF/bi-shRNAfurin DNA-transfected Autologous Tumor Immunotherapy (Vigil) in Metastatic Advanced Ewing's Sarcoma
Maurizio Ghisoli et al.
MOLECULAR THERAPY (2016)
Targeting Epithelial-Mesenchymal Transition (EMT) to Overcome Drug Resistance in Cancer
Bowen Du et al.
MOLECULES (2016)
Signaling Receptors for TGF-β Family Members
Carl-Henrik Heldin et al.
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2016)
Regulation of myeloid cells by activated T cells determines the efficacy of PD-1 blockade
Nina Eissler et al.
ONCOIMMUNOLOGY (2016)
TGF-β and VEGF cooperatively control the immunotolerant tumor environment and the efficacy of cancer immunotherapies
Tristan Courau et al.
JCI INSIGHT (2016)
Identification of a PEAK1/ZEB1 signaling axis during TGFβ/fibronectin-induced EMT in breast cancer
Megan Agajanian et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2015)
Stromal gene expression defines poor-prognosis subtypes in colorectal cancer
Alexandre Calon et al.
NATURE GENETICS (2015)
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer
Edward B. Garon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
R. J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway
Stephan Herbertz et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2015)
Abituzumab combined with cetuximab plus irinotecan versus cetuximab plus irinotecan alone for patients with KRAS wild-type metastatic colorectal cancer: the randomised phase I/II POSEIDON trial
E. ELez et al.
ANNALS OF ONCOLOGY (2015)
Second-line combination therapies in nonsmall cell lung cancer without known driver mutations
Maria-Virginia Bluthgen et al.
EUROPEAN RESPIRATORY REVIEW (2015)
The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence
Holly E. Barker et al.
NATURE REVIEWS CANCER (2015)
TGF-β: Duality of Function Between Tumor Prevention and Carcinogenesis
Daniel R. Principe et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2014)
Phase I Study of GC1008 (Fresolimumab): A Human Anti-Transforming Growth Factor-Beta (TGFβ) Monoclonal Antibody in Patients with Advanced Malignant Melanoma or Renal Cell Carcinoma
John C. Morris et al.
PLOS ONE (2014)
The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells
Dennis Lindau et al.
IMMUNOLOGY (2013)
Normalizing Tumor Microenvironment to Treat Cancer: Bench to Bedside to Biomarkers
Rakesh K. Jain
JOURNAL OF CLINICAL ONCOLOGY (2013)
Dependency of Colorectal Cancer on a TGF-β-Driven Program in Stromal Cells for Metastasis Initiation
Alexandre Calon et al.
CANCER CELL (2012)
Regulation of EMT by TGFβ in cancer
Carl-Henrik Heldin et al.
FEBS LETTERS (2012)
Randomized Phase II/III Trial Assessing Gemcitabine/Carboplatin and Methotrexate/Carboplatin/Vinblastine in Patients With Advanced Urothelial Cancer Who Are Unfit for Cisplatin-Based Chemotherapy: EORTC Study 30986
Maria De Santis et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Phase I Trial of bi-shRNAifurin/GMCSF DNA/Autologous Tumor Cell Vaccine (FANG) in Advanced Cancer
Neil Senzer et al.
MOLECULAR THERAPY (2012)
Targeting the TGFβ signalling pathway in disease
Rosemary J. Akhurst et al.
NATURE REVIEWS DRUG DISCOVERY (2012)
Induction of Heart Valve Lesions by Small-Molecule ALK5 Inhibitors
Mark J. Anderton et al.
TOXICOLOGIC PATHOLOGY (2011)
Long-term-survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer (vol 17, pg v118, 2006)
Hans von der Maase et al.
ANNALS OF ONCOLOGY (2011)
TGF-β Receptor Inhibitors Target the CD44high/Id1high Glioma-Initiating Cell Population in Human Glioblastoma
Judit Anido et al.
CANCER CELL (2010)
Molecular Mediators of Angiogenesis
Areck A. Ucuzian et al.
JOURNAL OF BURN CARE & RESEARCH (2010)
Polarization of Tumor-Associated Neutrophil Phenotype by TGF-β: N1 versus N2 TAN
Zvi G. Fridlender et al.
CANCER CELL (2009)
Transforming Growth Factor-Beta 1 (TGF-β1) Induces Angiogenesis Through Vascular Endothelial Growth Factor (VEGF)-Mediated Apoptosis
Giovanni Ferrari et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2009)
The epithelial-mesenchymal transition generates cells with properties of stem cells
Sendurai A. Mani et al.
CELL (2008)
Contextual regulation of inflammation: A duet by transforming growth factor-beta and interleukin-10
Ming O. Li et al.
IMMUNITY (2008)
Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium:: Results of a randomized phase 2 trial
Luigi Dogliotti et al.
EUROPEAN UROLOGY (2007)
Combining radiotherapy and immunotherapy: A revived partnership
S Demaria et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2005)
Long-term-survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer
H von der Maase et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Share Paper
